LIVA-HEALTHCARE
25.2.2020 09:02:15 CET | Business Wire | Press release
Liva Healthcare continues its impressive growth trajectory with the appointment of a Chief Commercial Officer (CCO) and 13 contract wins across healthcare providers, insurance and pharmaceutical organisations. This follows an investment of €8 million from three German venture funds in 2019.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200225005108/en/
Jonas Hjortshøj joins the senior leadership team at Liva as Chief Commercial Officer. Jonas brings over 10 years’ of experience from the pharmaceutical industry to the role, where he has held several roles with Novo Nordisk. Most recently, Jonas led the Commercial Partnering activities In the Obesity area at Novo Nordisk, as Associate Global Director. Here, Jonas was instrumental for developing a next generation digital platform for patients and driving the company’s digital health strategy for obesity.
Jonas will be taking his extensive experience and applying it to Liva’s ambitious growth plans among the pharmaceutical and health insurance industries. Already, Liva has kicked off 2020 with 13 new contract wins, including two NHS England CCGs, several multinational pharmaceutical companies, and a contract extension with the Municipality of Copenhagen.
Liva Healthcare is a Copenhagen and London based health tech company that provides patients with access to a dedicated health coach for professional guidance, support and empathy. Regular coaching sessions help patients tackle chronic conditions through sustainable lifestyle and behaviour changes. The Liva programme has been proven to halt and reverse the progression of Type 2 diabetes.
Kristoffer From, CEO at Liva Healthcare, says: “We are delighted to announce Jonas’ appointment at Liva. Jonas will be a key strategic asset as we embark on our ambitious European-wide expansion plan.
“Our digital coaching platform is proving instrumental in the global fight against Type 2 diabetes, obesity and heart disease. Our blend of scientific guidance and empathetic support results in long-term, sustainable, lifestyle changes for participants. We’re proud to support healthcare professionals with our scalable and cost-effective solution.”
Jonas Hjortshøj, CCO at Liva Healthcare, says: “I am excited and honoured to join Liva’s fast paced and innovative team. I am looking forward to enhancing our value-proposition and cementing our position as a partner to some of the largest health insurers and pharmaceutical companies, while executing on our ambitious international growth plans.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20200225005108/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Menicon’s Largest Malaysia Plant Begins Commercial Production5.2.2026 10:00:00 CET | Press release
- Strengthening Global Production Capacity for the Rapidly Growing 1-Day Lens Market Menicon Co., Ltd. is pleased to announce that its new manufacturing facility in Kedah, Malaysia, has commenced commercial production. The plant strengthens Menicon’s long-standing commitment to technological excellence, uncompromising quality, and a stable global supply of contact lenses. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260127294120/en/ The newly opened Malaysia plant is Menicon’s largest site to date and is dedicated exclusively to producing 1-DAY lenses. As global demand for 1-DAY lenses continues rising and the industry faces widespread supply constraints, Menicon has made significant capital investments to expand production capacity—even amid the uncertainties presented by the COVID-19 pandemic. Construction of phase 1, currently underway, will provide capacity for up to 500 million lenses per year. The construction plan i
Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 09:00:00 CET | Press release
Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release
Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom